What are Inva share price targets?

Their INVA share price targets range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.

What are Innoviva's share price targets?

3 analysts have issued twelve-month price targets for Innoviva's stock. Their INVA share price targets range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.

Should you buy Innoviva (Inva)?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INVA shares.

Does Inva have a competitive advantage?

Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of INVA’s competitive advantage.